What the evidence actually says about safety

The question patients most often bring before a consultation — 'is this safe?' — is one the published record can address with reasonable confidence for ChondroFiller® liquid.

Across clinical cohorts and post-market surveillance data covering more than 19,000 procedures performed globally, no pattern of serious device-related adverse events has emerged. That breadth of use without a discernible safety signal provides a more informative picture than any single trial could offer on its own.

The controlled evidence is consistent with this picture. In the first randomised multicentre trial (Schneider et al., 2016), zero adverse events were recorded among the 13 patients who received ChondroFiller, with MRI confirming progressive cartilage maturation at each follow-up point. The manufacturer's Clinical Evaluation Report — Version 09, dated April 2025 — assigns the device an approximately 0% complication rate across the reviewed literature. For context, that figure sits below the rates reported for autologous cell implantation procedures such as ACI and MACI, which the same comparative analysis places at up to 17%; the reoperation rate of roughly 3–8% is also substantially lower than microfracture (up to 41%) or MACI (up to 37%).

One further dimension concerns the collagen source. ChondroFiller uses murine-derived Type I collagen, and animal-derived biomaterials carry a theoretical immunogenicity concern in principle. In the human study literature reviewed to date, however, no clinically significant allergic or systemic reaction has been reported — a reassuring absence, even if the evidence base is not yet large enough to treat it as definitively ruled out.

How complication rates compare with other cartilage treatments

Placing any set of complication figures in context matters as much as the numbers themselves — particularly when comparing an outpatient injectable scaffold with procedures that involve theatre admission.

The comparative data in the manufacturer's Clinical Evaluation Report (CER v09, April 2025) shows ChondroFiller carrying a complication rate of approximately 0% and a reoperation rate of roughly 3–8%. Against those benchmarks, autologous cell implantation procedures such as ACI and MACI carry a published complication rate of up to 17% and a reoperation rate of up to 37%; microfracture sits at 0–7% for complications but rises sharply to up to 41% for reoperation. The reoperation gap is particularly striking for microfracture, where initially low complication rates can mask a higher downstream burden of revision procedures.

These figures should not be read as a direct clinical equivalence. Surgical cartilage interventions are typically reserved for larger or more complex defects, and the patient populations differ accordingly — making like-for-like comparison imprecise. Defect size, joint involved, patient age, and background pathology all influence which intervention is appropriate and what outcomes are achievable.

What can be said with more confidence is that the risk profiles belong to different clinical contexts. Theatre-related risks — complications from general anaesthesia, portal-site morbidity, surgical wound recovery — simply do not arise when treatment is delivered as an ultrasound-guided outpatient injection. That structural difference in procedural setting is itself a meaningful safety consideration for patients weighing their options at this stage of the treatment pathway.

The one identified risk: what happens when too much is injected

Fibrous tissue formation (FTF) — the growth of scar-like fibrous tissue within a repaired defect rather than hyaline-like cartilage — is the one adverse signal that appears consistently across the published ChondroFiller literature. It was identified in a 2025 study of 59 patients treated for cartilage damage associated with distal radius fractures (Matta et al.), and its pattern is clinically instructive.

FTF occurred exclusively in defects where ChondroFiller had been overfilled — applied above the level of the surrounding cartilage surface. In the same cohort, defects where the scaffold was applied flush produced no FTF at all, and no significant difference in broader complications was found between the treated and control groups. The evidence points clearly to fill volume precision, not the collagen material itself, as the operative safety variable.

This distinction has a practical implication for how the injection is performed. Placing any intra-articular injectable accurately requires image guidance, and ChondroFiller is no exception. Real-time ultrasound guidance during placement allows precise volume control and confirmation that the scaffold sits level with adjacent cartilage — directly addressing the overfill mechanism responsible for FTF. Ultrasound guidance is described across procedural documentation as essential to accurate application, much as it is for other advanced image-guided injections.

A related but separate consideration concerns early rehabilitation. A 2024 biomechanical study in porcine tissue found that in the first phase after application, the scaffold did not meaningfully reduce wear on opposing cartilage surfaces, attributed to initial mechanical instability before stable integration occurs. The authors recommended delaying full weight-bearing until the defect is stably filled. This is a rehabilitation-timing consideration rather than a material safety concern — but one that should inform post-injection guidance.

Who should not have ChondroFiller

Not every patient with a cartilage problem will be a suitable candidate, and knowing where ChondroFiller sits outside its safe-use envelope is as clinically important as understanding the evidence in its favour.

The clearest boundary from the published literature concerns advanced osteoarthritis. In the hip cohort study (26 patients, 12–60 months' follow-up), patients with pre-existing Tönnis Grade 2–3 OA at baseline consistently achieved poor outcomes — not because the injection caused direct harm, but because the degree of joint degeneration lay beyond what a focal scaffold can address. This distinction matters for how the contraindication is framed: advanced OA represents a setting where ChondroFiller is unlikely to help rather than one where it poses an active risk. An equivalent threshold applies in other joints, where Kellgren-Lawrence Grade III/IV radiographic change carries a similar implication for patient selection.

The absolute procedural contraindications occupy a different category. Active local or systemic joint infection, immunosuppression, and poorly controlled diabetes are exclusions that reflect conditions under which introducing any injectable scaffold into a joint would carry unacceptable risk, regardless of the material involved.

Beyond these categories, ChondroFiller's murine-derived collagen source is a factor clinicians review during pre-procedure assessment — particularly in patients with relevant allergy history or immunological considerations — as part of determining individual suitability.

These boundaries collectively explain why thorough assessment, including imaging and a detailed clinical history, is not administrative formality. It is the mechanism through which appropriate use — and therefore safe use — is established for each individual patient.

Where the evidence is strong — and where it still has limits

The evidence base supporting ChondroFiller is still maturing, and calibrating confidence appropriately means acknowledging that plainly rather than relying on volume of use alone.

Most of the published cohorts are small — the largest independent series number in the dozens of patients rather than hundreds — and a significant portion of the literature draws on manufacturer-commissioned or manufacturer-sponsored research. That pattern is not unusual in early-stage medical device evaluation, but it does mean that independent replication at scale remains limited. The pivotal randomised controlled trial (Schneider et al., 2016) compared ChondroFiller with microfracture in only 23 patients, and the microfracture arm experienced a high dropout rate, which constrains the comparative statistical conclusions that can be drawn from it.

The figure of more than 19,000 procedures performed globally is frequently cited as a real-world safety denominator. It is worth noting that this figure originates from post-market surveillance reporting and clinical tracking rather than an independently peer-reviewed journal study. What it represents is a large cumulative exposure with no emerging pattern of serious harm — a meaningful signal, even if not the same kind of evidence as a prospective controlled trial.

Long-term follow-up data beyond three to five years is sparse across all published cohorts. The durability of both the safety profile and structural repair beyond that window has not yet been confirmed in the literature.

Against these maturity caveats, a 2025 ex vivo study using human osteochondral tissue demonstrated a 2.4-fold increase in DNA content within ChondroFiller-treated defects by day 14, compared with untreated controls. This finding lends mechanistic credibility to the cell-recruitment rationale underpinning the scaffold — grounding the clinical observations in a biologically plausible human-tissue model.

Getting assessed: what patient selection involves

Safety in the right patient — that phrase, which runs through the published literature — only becomes meaningful when 'right patient' is defined for an individual case.

A formal assessment does that work. It looks beyond contraindication screening to establish whether a specific defect — its site, size, and grade — falls within the parameters the published cohorts actually studied, and whether the technical requirements for accurate collagen placement under ultrasound guidance are achievable for that joint. Both dimensions matter: the biology of the scaffold sets one boundary; the anatomy and accessibility of the defect may set another.

For patients at the enquiry stage — weighing this option against others, or uncertain whether their current imaging points in this direction — a structured intake typically covers joint history, current symptoms, and available imaging before any clinical decision is reached. That process is the appropriate starting point for anyone considering whether a collagen scaffold approach may suit their situation.

1. [1] Controlled, randomized multicenter study comparing ChondroFiller liquid with microfracturing (Schneider et al., 2016). (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1
2. [2] Cartilage reconstruction using Chondrofiller in intra-articular distal radius fractures (2025). (2025). https://doi.org/10.1186/s42836-025-00333-y https://doi.org/10.1186/s42836-025-00333-y
3. [3] Arthroscopic utilization of ChondroFiller gel for hip articular cartilage defects: cohort study 12–60 months (2021). (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
4. [4] Ex Vivo Osteochondral Biomimetic Platform for Cartilage Regeneration (2025). (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759
5. [5] Influence of cartilage defects and collagen gel on intact cartilage integrity: biomechanical in-vitro study (2024). (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z